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Abstract: Diabetic cardiomyopathy (DCM) has emerged as a relevant cause of heart failure among the
diabetic population. Defined as a cardiac dysfunction that develops in diabetic patients independently
of other major cardiovascular risks factors, such as high blood pressure and coronary artery disease,
the underlying cause of DCMremains to be unveiled. Several pathogenic factors, including glucose
and lipid toxicity, mitochondrial dysfunction, increased oxidative stress, sustained activation of the
renin-angiotensin system (RAS) or altered calcium homeostasis, have been shown to contribute to the
structural and functional alterations that characterize diabetic hearts. However, all these pathogenic
mechanisms appear to stem from the metabolic inflexibility imposed by insulin resistance or lack
of insulin signaling. This results in absolute reliance on fatty acids for the synthesis of ATP and
impairment of glucose oxidation. Glucose is then rerouted to other metabolic pathways, with harmful
effects on cardiomyocyte function. Here, we discuss the role that impaired cardiac insulin signaling
in diabetic or insulin-resistant individuals plays in the onset and progression of DCM.
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1. Introduction
Diabetes has become the most common metabolic disorder in the world and is nowadays
recognized by the World Health Organization as one of the most deadly non-communicable diseases
worldwide [1]. Cardiovascular diseases, including heart failure, ischemic heart, and stroke, lead the
ranking of causes of death among the diabetic population. Decades ago, the Framingham study
already showed that diabetes increases the risk of heart failure by two- and five-fold in men and
women, respectively [2]. The elevated rates of heart failure in diabetic patients could be attributed, in
part, to hypertension and atherosclerosis, two conditions that appear in diabetic patients with higher
frequency than in the non-diabetic population. In support of a causal relationship between diabetes
and cardiovascular diseases, it has been reported that an increase by 1% in the circulating levels of
HbA1c is associated with 8% increase in the risk of cardiovascular disease in type 2 diabetic patients,
even after adjusting for age, sex, obesity, alcohol, and tobacco consumption, hypertension or type and
duration of diabetes [3]. The risk increases by up to 30% among the type 1 diabetic population [4].
Conversely, 1% reduction in the HbA1c is associated with a 16% lower risk of developing chronic heart
failure [5]. These data support the notion that diabetes and the pathophysiologic alterations associated
with this endocrine disease represent a unique and independent risk factor for the development of
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cardiac dysfunction. In fact, it is now recognized that heart failure in diabetic individuals can also be
the consequence of diabetic cardiomyopathy (DCM), a pathological condition originally described
by Rubler and collaborators in 1972 that is defined as a heart failure syndrome appearing in diabetic
patients in the absence of coronary artery disease and high blood pressure [6]. However, the mechanistic
basis of the development of DCM is still poorly understood.
Loss or attenuation of insulin signaling is a distinctive trait of diabetes. Whereas lack of insulin
synthesis and/or secretion defines type 1 diabetes, tissue resistance to the action of insulin constitutes
the hallmark of type 2 diabetes, which represents more than 90% of the cases of diabetes. Insulin
resistance is considered the primary cause of type 2 diabetes. Although the metabolic disturbances
and cellular alterations that insulin resistance causes in major insulin target tissues, such as muscle,
liver or adipose tissue are well defined, less is known about the effects that insulin resistance has on
cardiac function. In this review, we summarize the current knowledge about the role that impaired
insulin signaling in heart plays in the pathogenesis of DCM.
2. Epidemiology and Pathophysiology of DCM
Even though increasingly recognized as a distinct pathological entity, only a few studies have
been conducted to estimate the prevalence of DCM within the diabetic population. Due to the small
number of participants and the disparity of the non-invasive imaging techniques used for the diagnosis
of DCM, such studies have yielded very variable prevalence rates of DCM, ranging from 30% to 60%,
depending on the study [7–9].
DCM is characterized by functional and structural changes in the heart of diabetic patients.
At the functional level, patients with DCM exhibit early development of left ventricular diastolic
dysfunction, featured by a reduction in the left ventricle filling velocity and delayed relaxation pattern.
Left ventricle systolic dysfunction, being recognized by diminished ejection fraction, develops later as
the disease progresses. Patients with DCM also show left ventricular hypertrophy, often accompanied
by fibrosis. Interstitial fibrosis increases in parallel to the progression of the disease as a result of
the replacement with the connective tissue of cardiomyocytes that have died from apoptosis and/or
necrosis [10,11]. The developed fibrosis contributes to cardiac stiffness and impaired contractility of
the heart. Another common feature of the heart of patients with DCM is cardiac steatosis [11], an
abnormal accumulation of triglycerides in the myocardium that reflects the metabolic derangements
occurring in cardiomyocytes of DCM patients (discussed in Section 3.1.3).
3. Insulin Resistance and the Pathogenesis of DCM
Established DCM is characterized by the clinical symptomatology described in the previous
paragraph. However, DCM has a long subclinical course before the appearance of the first overt cardiac
contractile and structural alterations, precluding an early detection and treatment of the disease. A
fundamental question is how diabetes alters proper cardiomyocyte function and leads to the cardiac
alterations that define DCM?
Numerous cellular and molecular factors have been proposed to play a causative role in the
cardiac functional defects found in patients with DCM. This includes excessive production of advanced
glycation end-products (AGEs), activation of the hexosamine biosynthetic pathway, lipotoxicity,
mitochondrial dysfunction, increased oxidative stress, activation of the RAS or impaired calcium
homeostasis (Figure 1). All these processes often concur in the same diabetic individual and interact
among each other to exacerbate the structural and functional alterations of the diabetic heart. Despite
their different nature and mechanisms of action, most of these pathogenic factors appear to stem from
the same fundamental process commonly altered in diabetic patients: Impaired insulin signaling.
Consequently, the reduction in the cardiac action of insulin could be considered as the primary cause
of DCM.
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Figure 1. Overview of the molecular derangements linked to the pathogenesis of DCM. As a result of 
the metabolic inflexibility imposed by impaired insulin signaling, glucose is not oxidized by 
cardiomyocytes but instead is diverted into other metabolic pathways that lead to the synthesis of  
AGEsor to the O-GlyNacylation of proteins. The increased intracellular accumulation of glucose also 
activates the RAS pathway and alters calcium homeostasis. In addition, hyperlipidemia facilitates 
fatty acid uptake and leads to lipotoxicity and cardiac steatosis. Furthermore, enhanced but 
inefficient oxidation of fatty acids leads to the production of reactive oxygen species (ROS) and 
further promotes mitochondrial dysfunction. All these factors have been shown to contribute to 
some extent to the functional alterations that characterize DCM. 
Although its role may seem obvious, the precise contribution of altered insulin signaling to the 
cardiac alterations in humans has not been comprehensively studied yet, and it remains 
controversial. In fact, some studies have reported a failure to find insulin resistance in hearts of the 
same type 2 diabetic patients in which other insulin target tissues, such as skeletal muscle or adipose 
tissue, exhibit a clear resistance to the action of the hormone [12,13]. In such studies, it has been 
speculated that, in the absence of cardiac insulin resistance, the hyperinsulinemia that accompanies 
type 2 diabetes at some point along the progression of the disease could contribute to cardiomyocyte 
hypertrophy, given the known action of insulin as an anabolic hormone involved in cell growth. 
Nevertheless, numerous studies in animal models clearly support the notion that cardiac insulin 
resistance does exist in the context of type 2 diabetes or obesity with whole-body insulin resistance 
[14–16]. 
3.1. Molecular and Cellular Mechanisms of DCM 
3.1.1. Increased Production of AGEs 
AGEs mostly consist of proteins, but also lipids and nucleic acids that have been glycated by the 
non-enzymatic action of reducing sugars. Secondary to the hyperglycemia that characterizes 
uncontrolled diabetic patients, AGEs promote the crosslinking of collagen and other extracellular 
Figure 1. vervie of the olecular derangements linked to the pathogenesis of DCM. As a result of the
metabolic inflexibility imposed by impaired insulin signaling, glucose is not oxidized by cardiomyocytes
but instead is diverted into other metabolic pathways that lead to the synthesis of AGEsor to the
O-GlyNacylation of proteins. The increased intracellular accumulation of glucose also activates the
RAS pathway and alters calcium homeostasis. In addition, hyperlipi emia facilitates fatty acid uptake
and leads to lipotoxicity and cardiac steatosis. Furthermore, enhanced but inefficient oxidation of fatty
acids l ads to the production of reactive oxygen species (ROS) and further promot s mitochondrial
dysfunction. All these factors h ve been shown to contribute to some extent to t e fu ctional alterations
that charac erize DCM.
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diabetic patients in which other insulin target tissues, such as skeletal muscle or adipose tissue, exhibit
a clear resistance to the actio of the ormone [12,13]. In such studies, it has been speculated that, i
th absence of cardiac insulin resistance, the hyperinsulinemia that accompanies type 2 diabetes at
some point along the progression of t e disease c uld contribute to cardiomyocyte hypertrophy, given
the known action of insuli as an anabolic hormone involved in cell growth. Nevertheless, numerous
studies in animal models clearly support the notion th t cardiac insulin resistance does exist in the
context of type 2 diabetes or besity with whole-body insulin resistance [14–16].
3.1. Molecular and Cellular Mechanisms of DCM
3.1.1. Increased Production of AGEs
AGEs mostly cons st of proteins, but also lipids and nucleic acids that have been glycated by
the non-enzymatic action of reducing sugars. Secondary to the hyperglycemia that characterizes
uncontrolled diabetic patients, AGEs promote the crosslinking of collagen and other extracellular matrix
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proteins, impairing their normal degradation (Figure 2). The changes in the mechanical properties of
the extracellular matrix proteins lead to increased fibrosis and myocardial stiffness [17]. Furthermore,
the interaction of AGEs with specific receptors (RAGEs) leads to enhanced expression of collagen and
other extracellular matrix proteins through the upregulation of TGFβ, contributing by this means
to the exacerbation of the cardiac dysfunction induced by fibrosis. In addition, AGEs induce the
expression of their specific RAGEs receptors, and generate a positive feedback loop that exacerbates the
negative impact of AGEs on cardiac function. AGEs-RAGE signaling also activates a pro-inflammatory
response through MAPK, JNK, and NF-kB that leads to the recruitment and activation of T helper
lymphocytes and induces the production of pro-fibrotic cytokines, favoring interstitial fibrosis and
impairing diastolic function [18]. The relevant contribution of AGEs to the etiopathogenesis of DCM
has been demonstrated by the use of molecules with RAGE antagonistic activity, which were able to
improve the systolic function and reduce the expression of pro-fibrotic proteins in a mouse of type 2
diabetes associated with obesity [19].
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Figure 2. Pathogenic mechanisms of hyperglycemia through the production of AGEs. 
Hyperglycemia and inhibition of glycolysis favor the accumulation of glucose and the production of 
AGEs in cardiomyocytes. Activation of AGE–specific receptors (RAGE) signaling pathway increases 
collagen production and turns on intracellular inflammatory pathways, both of which enhance 
fibrosis. 
3.1.3. Lipotoxicity 
As previously mentioned, DCM is often associated with the accumulation of lipids in the 
myocardium. The cardiac steatosis observed in diabetic patients and animal models of DCM is the 
result of increased fatty acid uptake and storage under the form of triglycerides (Figure 3). 
Intracellular lipid accumulation is unequivocally favored by the hyperlipidemic milieu that 
characterizes diabetes, which results from enhanced hepatic lipid synthesis and uncontrolled 
lipolysis in adipose tissues. Although triglyceride accumulation within cardiomyocytes is the most 
evident and detectable manifestation of intracellular lipid accumulation, lipotoxicity cannot be 
attributed to triglycerides themselves but to the accumulation of noxious lipid intermediates, such as 
ceramides, diacylglycerols or acylcarnitines [26,27]. The accumulation of these lipid species 
promotes mitochondrial dysfunction, endoplasmic reticulum stress or apoptosis by mechanisms 
that are not fully understood. For instance, ceramides and diacylglycerols have been shown to 
activate different protein kinase C isoforms, like PKCβ, PKCδ, or PKCθ. Activation of 
PKCs-mediated signaling pathways promotes inflammation, fibrosis or cell death, all of which have 
been shown to contribute to cardiac dysfunction [28]. Excessive lipid uptake by the myocardium also 
alters cardiomyocyte metabolism, favoring fatty acid oxidation in detriment of glucose as the main 
energetic substrate [29]. The increased flux of fatty acids into the mitochondria for their oxidation 
results in uncoupling of mitochondria and excessive production of ROS (see Section 3.1.4), which 
promote cell death and contribute to cardiac dysfunction [30]. 
Figure 2. Pathogenic mechanisms of hyperglycemia through the production of AGEs. Hyperglycemia
and inhibition of glycolysis favor the accumulation of glucose and the production of AGEs in
cardiomyocytes. Activation of AGE–specific receptors (RAGE) signaling pathway increases collagen
production and turns on intracellular inflammatory pathways, both of which enhance fibrosis.
3.1.2. Increased Substrate Flux through the Hexosamine Biosynthetic Pathway
Once into the cell, accumulated glucose can be diverted towards the hexosamine biosynthetic
pathway. The hexosamine pathway pr vides the UDP-N-acetylglucosamine that serves as a
donor for O-linked-β-N-acetylgluc samine (O-GlcNAc) protein modification. Post-translational
O-GlcNAcylation of targeted proteins, inclu ing transcription factors, structural proteins or enzymes,
leads to changes in their activity and f ction. Whereas the flux of glucose through the hexosamine
pathway under non-pathological conditi ns must be considered as a regulatory mecha ism of the
cellular function in response to n trients, the sustained activation of this pathway, as it occurs in
diabetes, is known to have detrimental effects.
Increased accumulation of O-GlcNAcylated proteins has been bserve i the heart of rodent
models of type 1 and type 2 di betes [20,21]. Several rel v nt cardiac proteins have been found
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to be O-GlcNAcylated, including phospholamban (a regulator of the calcium pump SERCA2a),
calmodulin-dependent protein kinase II (CAMKII) or proteins of the contractile machinery (i.e., actin
and troponin I) [22,23]. The O-GlcNAcylation of phospholamban and CAMKII is compatible with the
contractile dysfunction observed in DCM that results from impaired calcium handling (see Section 3.1.6).
On the other hand, O-GlcNAcylation of contractile proteins has been shown to alter their sensitivity
to calcium, and by this means it contributes to the contractile dysfunction of the diabetic heart [24].
Although the negative effects on cardiomyocyte function of increased flux through the hexosamine
biosynthetic pathways and the resulting protein O-GlcNAcylation have been demonstrated in vitro
using cultured cardiac cells [25], compelling evidence that unequivocally demonstrates the contribution
of the hexosamine pathway to DCM in vivo is still missing.
3.1.3. Lipotoxicity
As previously mentioned, DCM is often associated with the accumulation of lipids in the
myocardium. The cardiac steatosis observed in diabetic patients and animal models of DCM is the result
of increased fatty acid uptake and storage under the form of triglycerides (Figure 3). Intracellular lipid
accumulation is unequivocally favored by the hyperlipidemic milieu that characterizes diabetes, which
results from enhanced hepatic lipid synthesis and uncontrolled lipolysis in adipose tissues. Although
triglyceride accumulation within cardiomyocytes is the most evident and detectable manifestation of
intracellular lipid accumulation, lipotoxicity cannot be attributed to triglycerides themselves but to the
accumulation of noxious lipid intermediates, such as ceramides, diacylglycerols or acylcarnitines [26,27].
The accumulation of these lipid species promotes mitochondrial dysfunction, endoplasmic reticulum
stress or apoptosis by mechanisms that are not fully understood. For instance, ceramides and
diacylglycerols have been shown to activate different protein kinase C isoforms, like PKCβ, PKCδ,
or PKCθ. Activation of PKCs-mediated signaling pathways promotes inflammation, fibrosis or cell
death, all of which have been shown to contribute to cardiac dysfunction [28]. Excessive lipid uptake
by the myocardium also alters cardiomyocyte metabolism, favoring fatty acid oxidation in detriment
of glucose as the main energetic substrate [29]. The increased flux of fatty acids into the mitochondria
for their oxidation results in uncoupling of mitochondria and excessive production of ROS (see
Section 3.1.4), which promote cell death and contribute to cardiac dysfunction [30].
3.1.4. ROS Production and Mitochondrial Dysfunction
Oxidative stress has been identified as a major contributing factor to the onset and development of
DCM. Numerous studies in animal models of type 1 or type 2 diabetes and few others in humans have
demonstrated the presence of oxidative stress in the diabetic heart. For instance, increased levels of
hydrogen peroxide, which correlate with a high content of peroxidized lipids and nitrosylated proteins,
as well as cell death by apoptosis, have been found in hearts of patients with type 2 diabetes [31,32].
Similarly, ROS-induced modification of lipids and proteins has been described in several rodent
models of DCM, together with other markers of oxidative stress, such as altered expression levels
of detoxifying enzymes (i.e., catalase, peroxidase) or gluthation [33–37]. In support of a relevant
causative contribution of oxidative stress to the pathogenesis of DCM, reduction of ROS levels by the
administration of antioxidants, such as dehydroepiandrosterone (DHEA) [33] to rodent models, as
well as the ectopic overexpression of catalase [37] or superoxide dismutase [35], have been shown to
reduce cardiac fibrosis and to improve cardiac contractile function.
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Figure 3. Lipotoxicity as a main pathogenic mechanism of DCM. Increased uptake of fatty acids by 
cardiomyocytes favors their accumulation as triglycerides within the cells. Moreover, inefficient 
oxidation of fatty acids by dysfunctional mitochondria leads to excessive production of ROS and cell 
death. Lipid intermediates and other lipid species, such as ceramides and diacylglycerols, also 
accumulate in cardiomyocytes and activate PKCs, promoting fibrosis and cell death. 
3.1.4. ROS Production and Mitochondrial Dysfunction  
Oxidative stress has been identified as a major contributing factor to the onset and development 
of DCM. Numerous studies in animal models of type 1 or type 2 diabetes and few others in humans 
have demonstrated the presence of oxidative stress in the diabetic heart. For instance, increased 
levels of hydrogen peroxide, which correlate with a high content of peroxidized lipids and 
nitrosylated proteins, as well as cell death by apoptosis, have been found in hearts of patients with 
type 2 diabetes [31,32]. Similarly, ROS-induced modification of lipids and proteins has been 
described in several rodent models of DCM, together with other markers of oxidative stress, such as 
altered expression levels of detoxifying enzymes (i.e., catalase, peroxidase) or gluthation [33–37]. In 
support of a relevant causative contribution of oxidative stress to the pathogenesis of DCM, 
reduction of ROS levels by the administration of antioxidants, such as dehydroepiandrosterone 
(DHEA) [33] to rodent models, as well as the ectopic overexpression of catalase [37] or superoxide 
dismutase [35], have been shown to reduce cardiac fibrosis and to improve cardiac contractile 
function. 
It is necessary to remark that mitochondria are the major source of cellular ROS. It has been 
suggested that an impaired capacity of mitochondria to efficiently oxidize substrates, such as fatty 
acids, would favor the production of ROS. In this regard, numerous studies have comprehensively 
demonstrated that diabetic patients exhibit a reduction of mitochondrial mass and/or activity in 
multiple tissues, including skeletal muscle and adipose tissue (reviewed in [38]). The heart does not 
appear to be an exception and evidence of impaired mitochondrial function, such as a decrease in 
the PCr/ATP ratio, has been observed in diabetic patients, tightly correlating with diastolic 
dysfunction [39]. Impaired mitochondrial oxidative capacity has also been observed in several 
rodent models of type 1 or type 2 diabetes [15,30,35,40,41]. The primary cause of such mitochondrial 
dysfunction in diabetic individuals is unclear. Whereas some authors have reported a decrease in the 
Figure 3. Lipotoxicity as a main pathogenic mechanism of DCM. Increased uptake of fatty acids
by cardiomyocytes favors their accumulation as triglycerides within the cells. Moreover, inefficient
oxidation of fatty acids by dysfunctional mitochondria leads to excessive production of ROS and
cell death. Lipid intermediates and other lipid species, such as ceramides and diacylglycerols, also
accu ulate in cardio yocytes and activate PKCs, pro oting fibrosis and cell death.
It is necessary to remark that mitochondria are the major source of cellular ROS. It has been
suggested that an impaired capacity of mitochondria to efficiently oxidize substrates, such as fatty
acids, would favor the production of ROS. In this regard, numerous studies have comprehensively
demonstrated that diabetic patients exhibit a reduction of mitochondrial mass and/or activity in multiple
tissues, including skeletal muscle and adipose tissue (reviewed in [38]). The heart does not appear to be
an exception and evidence of impaired mitochondrial function, such as a decrease in the PCr/ATP ratio,
has been observed in diabetic patients, tightly correlating with diastolic dysfunction [39]. Impaired
mitochondrial oxidative capacity has also been observed in several rodent models of type 1 or type 2
diabetes [15,30,35,40,41]. The primary cause of such mitochondrial dysfunction in diabetic individuals
is unclear. Whereas some authors have reported a decrease in the expression of genes encoding for
mitochondrial proteins of the OxPhos system [15,30], some others have reported the absence or even
an increase in the expression of such genes [35,42]. Regardless of whether the mitochondrial oxidative
machinery is reduced or not in diabetic individuals, numerous studies in rodent models have shown
that the heart of diabetic individuals exhibits increased fatty acid uptake and oxidation, a metabolic
signature of diabetic heart. The exacerbated fatty acid oxidation observed in diabetic hearts is, at
least in part, the result of the increased levels of circulating fatty acids that characterizes the diabetic
milieu. Still, the question is: How increased fatty acid oxidation results in mitochondrial dysfunction
and increased ROS production? According to the data gathered from rodent models of diabetes, it is
thought that mitochondria of diabetic hearts cannot handle the overwhelming amount of fatty acids
that are delivered into the cardiomyocytes. This results in inefficient oxidation of lipids, the uncoupling
of mitochondria and enhanced production of ROS [30,43]. In turn, the abnormally high levels of ROS
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produced within cardiac cells further favor mitochondrial dysfunction, aggravating the worsening of
cardiac energetics and further reducing cardiac efficiency and function.
3.1.5. Activation of RAS
Diabetes has been documented to suppress the circulating RAS, causing a decrease in the blood
levels of renin and angiotensin II [44]. Paradoxically, local activation of the RAS pathway, independently
of the global circulating RAS, has been described in several tissues of diabetic patients, including
heart [45]. The cardiac activation of RAS has been suggested to contribute to cardiac dysfunction in
individuals with DCM by promoting fibrosis, increased oxidative stress, and cardiomyocyte death.
Diabetes activates local RAS by different means (Figure 4). It has been demonstrated that
hyperglycemia can directly stimulate the production of angiotensin II in cardiomyocytes, an effect that
contributes to cardiomyocyte death by apoptosis through the activation of p53 [45,46]. In addition,
diabetes exacerbates the expression of angiotensin receptor 1 (AT1R) in heart, amplifying the activation
of RAS signaling in cardiomyocytes [47]. Other indirect mechanisms by which diabetes increases
the activity of cardiac RAS are related to dyslipidemia and the exacerbated production of AGEs and
ROS associated with diabetes, all of which stimulate the cardiac RAS pathway by up-regulating AT1R
expression [48]. Although most of the experimental evidence linking abnormal RAS activation with
DCM has been obtained in rodent models of diabetes, the significant improvement of left ventricle
hypertrophy and systolic function in diabetic patients treated with the RAS antagonist aliskiren, a renin
inhibitor, clearly supports the notion that RAS activation is a major contributor to the pathogenesis of
DCM [49,50].
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Figure 4. Role of the RAS and the hexosamine biosynthetic pathways in DCM. High intracellular 
glucose levels promote the activation of the hexosamine biosynthetic pathway, leading to the 
O-GlcNAcylation of key proteins related to the cardiac contractile function or involved in calcium 
homeostasis. In addition, high glucose levels directly stimulate the production of angiotensinogen II, 
leading to the activation of RAS in cardiomyocytes and cell death. AGEs and ROS promote the 
synthesis of the ATR1, further enhancing RAS activation. 
3.2. Effects of Insulin Resistance on Metabolic Flexibility and its Implications on Cardiac Dysfunction 
Reduced or complete lack of insulin signaling is a hallmark of diabetes. Whereas in type 1 
diabetic individuals insulin signaling is absent as a result of the lack of insulin synthesis and/or 
secretion, type 2 diabetes is characterized by impaired, but still active, insulin signaling. Regardless 
of the type of diabetes, altered insulin signaling in diabetic individuals leads to profound, but 
similar, alterations in metabolism, which is characterized by reduced insulin-dependent glucose 
uptake and utilization, and exacerbated usage of lipids as metabolic substrates. Altered metabolism 
directly impacts cardiomyocyte function, ultimately being accountable for most of the functional 
and structural alterations found in DCM. 
The heart requires an enormous amount of energy to maintain its contractile function. Cardiac 
cells can use a wide variety of substrates as a source of energy, including amino acids and ketone 
bodies, although carbohydrates and lipids are their preferred substrates to obtain ATP via oxidative 
phosphorylation in mitochondria. Overall, a healthy heart predominantly obtains around 70% of the 
energy from fatty acids and 20–30% from glucose [57]. However, the use of carbohydrates or lipids 
varies along the day depending on substrate availability and is tightly controlled by hormones, like 
insulin and glucagon. During the feeding state, secretion of insulin inhibits adipose tissue lipolysis 
and promotes hepatic lipogenesis, decreasing the availability of fatty acids for the heart and other 
tissues. Simultaneously, insulin promotes glucose uptake and utilization by cardiomyocytes. 
Contrarily, in fasting conditions, the decrease in insulin levels and the rise in glucagon decrease 
glucose uptake and oxidation, while promoting fatty acid utilization. Therefore, metabolic 
flexibility, the capacity to switch from one substrate to another, is the main feature of a healthy heart. 
Figure 4. Role of the RAS and the hexosamine biosynthetic pathways in DCM. High intracellular glucose
levels promote the activation of the hexosamine biosynthetic pathway, leading to the O-GlcNAcylation
of key proteins related to the cardiac contractile function or involved in calcium homeostasis. In
addition, high glucose levels directly stimulate the production of angiotensinogen II, leading to the
activation of RAS in cardiomyocytes and cell death. AGEs and ROS promote the synthesis of the ATR1,
further enhancing RAS activation.
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3.1.6. Calcium Mishandling
Calcium is an essential regulator of muscle contraction. Upon cardiomyocyte depolarization,
calcium enters the cell through the L-type calcium channels and promotes the release of more
calcium from the sarcoplasmic reticulum. The large increase in intracellular calcium concentration
triggers cellular contraction by binding to the contractile proteins. Subsequently, calcium returns
to the sarcoplasmic reticulum through the action of several ion transporters, including the
sarcoplasmic reticulum calcium pump (SERCA2a), the sodium–calcium exchanger and the sarcolemmal
calcium ATPase.
Alterations in calcium homeostasis have been linked to the functional derangements found in heart
of diabetic individuals. Studies in animal models of diabetes have reported that calcium release and
reuptake by the sarcoplasmic reticulum is depressed in cardiomyocytes of diabetic individuals [51–54].
As a result, calcium transients are smaller and slower, altering the normal contractile activity of the
heart. Several studies coincide in pointing at reduced activity of the SERCA2a pump, but also of others
calcium transporters, such as the sodium–calcium exchanger or the sarcolemmal calcium ATPase,
the expression of which is reduced in heart of diabetic individuals, as one of the major causes of the
disturbances in calcium handling in DCM [55,56].
3.2. Effects of Insulin Resistance on Metabolic Flexibility and its Implications on Cardiac Dysfunction
Reduced or complete lack of insulin signaling is a hallmark of diabetes. Whereas in type 1
diabetic individuals insulin signaling is absent as a result of the lack of insulin synthesis and/or
secretion, type 2 diabetes is characterized by impaired, but still active, insulin signaling. Regardless of
the type of diabetes, altered insulin signaling in diabetic individuals leads to profound, but similar,
alterations in metabolism, which is characterized by reduced insulin-dependent glucose uptake and
utilization, and exacerbated usage of lipids as metabolic substrates. Altered metabolism directly
impacts cardiomyocyte function, ultimately being accountable for most of the functional and structural
alterations found in DCM.
The heart requires an enormous amount of energy to maintain its contractile function. Cardiac
cells can use a wide variety of substrates as a source of energy, including amino acids and ketone
bodies, although carbohydrates and lipids are their preferred substrates to obtain ATP via oxidative
phosphorylation in mitochondria. Overall, a healthy heart predominantly obtains around 70% of the
energy from fatty acids and 20–30% from glucose [57]. However, the use of carbohydrates or lipids
varies along the day depending on substrate availability and is tightly controlled by hormones, like
insulin and glucagon. During the feeding state, secretion of insulin inhibits adipose tissue lipolysis and
promotes hepatic lipogenesis, decreasing the availability of fatty acids for the heart and other tissues.
Simultaneously, insulin promotes glucose uptake and utilization by cardiomyocytes. Contrarily, in
fasting conditions, the decrease in insulin levels and the rise in glucagon decrease glucose uptake and
oxidation, while promoting fatty acid utilization. Therefore, metabolic flexibility, the capacity to switch
from one substrate to another, is the main feature of a healthy heart.
The diabetic heart, however, is characterized by an unusual metabolic inflexibility. Indeed, the
diabetic heart is unable to use glucose for the production of ATP and exclusively relies on fatty acids
for such purpose. Such metabolic defect can be almost exclusively attributed to blunted insulin
signaling. Thus, despite the hyperglycemia that characterizes the diabetic milieu, impaired insulin
action results in reduced glucose uptake by cardiomyocytes through the insulin-sensitive glucose
transporter GLUT4, which represents 70% of glucose transporters in the heart. Nevertheless, glucose
gets into cardiomyocytes by other insulin-independent glucose transporters, such as the sodium
glucose co-transporter SGLT1, whose expression is increased in diabetic individuals [58]. Intracellular
glucose accumulation is also favored by a reduction in the glycolytic flux as a result of the inhibition of
the pyruvate dehydrogenase complex (PDH) by pyruvate dehydrogenase kinase 4 (PDK4), whose
expression and activity are dramatically increased in diabetic heart as a consequence of the negative
action of insulin on Pdk4 gene expression [59]. Increased intracellular accumulation of glucose,
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as mentioned in previous sections, is known to cause toxic effects by enhancing the formation of
AGEs. Furthermore, high glucose intracellular concentration favors the rerouting of glucose into the
hexosamine biosynthetic pathway, resulting in the O-GlcNAcylation of target proteins. As discussed
earlier (see Sections 3.1.1 and 3.1.2), the increased flux of glucose through the AGE and hexosamine
pathways contributes to the functional derangements of the diabetic heart.
Insulin resistance or lack of insulin signaling in adipose tissue of diabetic individuals impairs
the inhibition of triglyceride lipolysis by insulin, leading to high levels of circulating fatty acids. This,
together with the incapacity of diabetic heart to use glucose as a substrate for the production of
ATP, favors the uptake and oxidation of fatty acids. Still, as mentioned previously, the inability of
cardiac mitochondria to deal with such an overwhelming amount of lipids results in lipotoxicity. The
exacerbated lipid metabolism observed in DCM is not simply the result of increased lipid uptake
and increased flux through oxidative pathways as a direct result of increased activity of catabolic
enzymes, but it implies a complete reprogramming of the entire cellular metabolism through broad
changes in the transcriptional programs that govern lipid metabolism. Indeed, gene expression
profiling studies in hearts of db/db diabetic mice have revealed an overall increase in the expression
of genes related to different aspects of lipid metabolism, including triglyceride hydrolysis, cellular
transport and both peroxisomal and mitochondrial β-oxidation of fatty acids [42]. In addition, an
increase in the expression of genes related to lipid synthesis has been also observed, which together
with the increase in the expression of genes involved in fatty acids transport yields a plausible
explanation for the cardiac steatosis that characterizes DCM. The metabolic reprogramming of diabetic
hearts appears mediated at the transcriptional level by the activation of hormone nuclear receptors
estrogen-related receptor γ (ERRγ) and Peroxisome Proliferator-Activated Receptor α (PPARα), the
expression of which is increased in diabetic models of DCM [42,60]. Both ERRs and PPARα are
well-known regulators of oxidative metabolism by regulating, among others, the expression of genes
involved in fatty acid catabolism [61,62]. In support of PPARα playing a relevant role in the metabolic
reprogramming of diabetic hearts, transgenic mice that overexpress PPARα specifically in heart show
an increase in fatty acid oxidation rates that is accompanied by cardiomyocyte hypertrophy and
contractile dysfunction [60,63]. On the other hand, a key role of ERRγ in DCM has been recently
suggested by in vitro studies showing that adenoviral-mediated ectopic overexpression of ERRγ in
mouse cardiomyocytes is sufficient to recapitulate most of the alterations found in diabetic hearts,
including increased Pdk4 expression, enhanced fatty acid oxidation, activation of the transcriptional
program related to lipid metabolism, particularly lipid catabolism, and increased cardiomyocyte
size [42]. Interestingly, in addition, ERRγ controls the expression of PPARα by directly binding to the
Ppara promoter [42,64], highlighting the role of the ERRγ-PPARα axis in the metabolic reprogramming
of the diabetic heart.
4. Rodent Models of Impaired Insulin Signaling for the Study of DCM
The studies aimed at unraveling the factors involved in the onset and progression of DCM have
been based on the use of rodent models. Still, the use of cultured cells has been instrumental in precisely
defining the mechanisms of action and pathogenic relevance of such mechanisms. The rat H9C2 and
mouse HL-1 cell lines together with primary rat neonatal cardiomyocytes have been extensively used.
However, these in vitro models are not exempt from severe limitations. Thus, whereas HL-1 cells
have an atrial origin, H9C2 myoblasts are frequently used without any further differentiation into
mature muscular cells, precluding in both cases any conclusion about the real impact of the results
obtained on adult ventricular cardiomyocytes. More recently, the use of induced pluripotent stem cell
(iPSC)-derived cardiomyocytes has proven to be very valuable for the study of DCM [65,66]. However,
one of the major drawbacks of this model, but which can be extended to others cellular models, is
the difficulty to accurately reproduce all the cellular and environmental features the define DCM,
including glucotoxicity, lipotoxicity, and insulin resistance. Although this has been partially achieved
by culturing iPSC-derived cardiomyocytes in media with high levels of fatty acids (i.e., palmitate) and
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glucose [67,68], the culture conditions are far from accurately reproduce the complex metabolic and
hormonal features, as well as (dys)functional characteristics found in diabetic subjects. Therefore, the
use of animal models still remains the best approach for the study of DCM.
4.1. Genetic Models of Cardiac-Specific Disruption of Insulin Signaling for the Study of DCM
The use of genetically-engineered mouse models that lack specific components of the insulin
signaling pathway has proven extremely useful to precisely define the contribution of impaired insulin
signaling to DCM without the confounding effects derived from the systemic metabolic alterations
found in genetic- or diet-induced models of insulin resistance/diabetes associated with chronic obesity.
Mice lacking insulin receptor (IR) specifically in the heart show impaired cardiac function
accompanied by decreased heart size, which results in part from a reduction in cardiomyocyte
size [69,70]. The reduction in heart size found in heart-specific IR knockout mice highlights the
relevance of proper insulin signaling in cardiac growth, beyond its effects on metabolism. At the
metabolic level, however, loss of insulin signaling causes an unexpected increase in basal glycolysis
rates, although both glucose and fatty acid oxidation are reduced. The loss of IR results in a reduction
in GLUT1 but, surprisingly, such loss is accompanied by an increase in GLUT4, which is apparently
sufficient to compensate for impaired glucose transport in the absence of proper insulin signaling.
Contrary to what it has been observed in rodent models of obesity-associated type 2 diabetes or
streptozotocin-induced type 1 diabetes (see Section 4.2), mice lacking IR exhibit a reduction in the
expression of fatty acid oxidation genes (Mcad, Lcad, Vlcad, Ppara), as well as a reduction in the
expression of Pdk4, what would explain the reduced fatty acid oxidation rates found in these mice [69].
Knockout mice with simultaneous deletion of genes encoding for insulin receptor substrate-1
and -2 (IRS-1 and IRS-2) specifically in heart show a phenotype similar to that of heart-specific
IR knockout mice. Far from showing cardiac hypertrophy, cardiac-specific IRS1/2 knockout mice
develop dilated cardiopathy, characterized by increased diameter of cardiac chambers and thinned
cardiac walls [71]. Loss of IRS1/2 leads to increased cardiomyocyte death and interstitial fibrosis that
contribute to depressed cardiac function and early death by two months of age. Consistent with lack
of proper insulin signaling and contrary to what was described for heart-specific IR knockout mice,
cardiac-specific IRS1/2 knockout mice exhibit a reduction in the expression of genes related to glucose
metabolism (i.e., Glut1, Glut4, Gck) and an increase in the expression of Pdk4. However, in contrast with
the characteristic gene expression pattern of DCM, the expression of genes related to lipid catabolism
(i.e., Vlcad) was reduced [71], what is suggestive of a decreased fatty acid oxidation in the absence
of IRS1/2.
3-phosphoinositide-dependent kinase-1 (PDK1) is another key component of the insulin signaling
pathway that is required for the activation of AKT/PKB. Mice lacking PDK1 specifically in the heart
show a phenotype very similar to the one shown by the models described earlier. Cardiac-specific
PDK1 knockout mice die around 5–11 weeks of age from severe heart failure [72]. Hearts from mice
lacking PDK1 exhibit clear signs of wall thinning accompanied by interstitial fibrosis and reduced
cardiomyocyte size. To overcome the early lethality of the cardiac-specific PDK1 knockout mice, Ito
and collaborators generated a tamoxifen-inducible cardiac-specific PDK1 knockout mouse model [73].
Lack of PDK1 during adulthood leads to death from heart failure 5–15 weeks after Pdk1 deletion. Wall
thinning and chamber dilation, together with increased fibrosis and cardiomyocyte apoptosis were
developed soon after Pdk1 was deleted [73]. Unfortunately, how metabolism is affected by the lack of
PDK1 in those mice has not been addressed.
4.2. Rodent Models of Diabetes or Systemic Insulin Resistance for the Study of DCM
The mouse models defective in specific components of the insulin signaling pathway in cardiac
tissue highlight the relevance of insulin for proper cardiac function and development, as well as in
cardiomyocyte growth and survival. However, complete lack of insulin signaling specifically in the
heart does not always phenocopy all the cellular and molecular derangements found in DCM. This
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suggests that DCM is the result of complex interactions between cardiac cells in which insulin signaling
is impaired and the diabetic milieu that results from insulin resistance or absence of insulin signaling
in other tissues. In this regard, the use of rodent models of diabetes or systemic insulin resistance
has proven very valuable for the study of DCM. The use of such rodent models has been extensively
reviewed elsewhere [15] and, therefore, here, we will only highlight some of the main features of the
most commonly used models.
Streptozotocin (STZ)-induced type 1 diabetes rat or mouse models have been frequently used
for the study of DCM. The toxic effects of STZ on pancreatic β-cells result in loss of β-cells, with the
consequent deficiency in insulin secretion, despite insulin sensitivity being maintained in peripheral
tissues. STZ-induced diabetes rodent models exhibit cardiac dysfunction, the severity of which is
proportional to the time of diabetes evolution. Both systolic and diastolic left ventricular dysfunction
has been reported in some studies, associated with reduced ejection fraction and/or reduced rate of
relaxation [74–76]. However, other studies have reported no major alterations in heart function [77].
Nevertheless, STZ-induced type 1 diabetic mice and rats show most of the cellular and metabolic
features described in DCM, including cardiomyocyte hypertrophy and death, oxidative stress, fibrosis,
decreased cardiac efficiency, altered calcium homeostasis and increased expression of genes related to
fatty acid uptake and oxidation [33,45,60,75,76,78].
Rodent models of severe insulin resistance and type 2 diabetes associated with obesity as a
result of a defect in the leptin signaling pathway have been also extensively used for the study of
DCM. The ob/ob mice show a recessive mutation in the gene encoding for leptin, an adipose-specific
anorexigenic hormone, whereas the db/db mice -and their equivalent Zucker diabetic fatty (ZDF)
rats- are characterized by a point mutation in the leptin receptor gene. As a result of the disruption
in leptin signaling, ob/ob and db/db mice and ZDF rats are hyperphagic and develop severe obesity,
insulin resistance and type 2 diabetes. Although both models show impaired leptin signaling, a major
difference between ob/ob and the db/db mice is the temporal course of diabetes, which develops earlier in
db/db mice. This might be responsible for the subtle differences found between ob/ob and db/db mice with
regard to the cardiac outcome. In addition, the technical approaches used in the different studies to
evaluate cardiac structure and function could be blamed for the variable, sometimes even contradictory,
results obtained in different studies using the same mouse model. For instance, echocardiographic
studies have yielded very variable results with regard to cardiac structure and function. Thus, whereas
a reduction in left ventricular mass and decreased diameter of the ventricular cavities, both at systole
or diastole, have been reported by some studies in db/db mice [42], others researchers have reported an
increased in the left ventricle internal cavity diameter without major changes in ventricular mass [41,79]
or the lack of noticeable and consistent structural alterations [80–83]. Contrarily, the assessment of
cardiac function in isolated working hearts unequivocally revealed altered cardiac function in hearts of
ob/ob and db/db mice, both of which exhibit a decrease in left ventricle systolic pressure and cardiac
output (measured as aortic flow) and an increase in left ventricle developed pressure [29,30,43,55,84–86].
Moreover, ob/ob and db/db mice and ZDF rats accurately reproduce all the cellular and metabolic traits
that define DCM, including cardiomyocyte hypertrophy, cardiac steatosis and cell death [27,42,80,81].
At the metabolic level, type 2 diabetic rodent models show metabolic inflexibility, characterized by
reduced glucose oxidation and increased fatty oxidation and oxidative stress [29,43,84–86]. Consistent
with the increase in fatty acid oxidation, these rodent models exhibit increased expression of genes
involved in lipid uptake, mobilization, and oxidation [42,43,60,85].
5. Conclusions
From the numerous epidemiologic studies that show a steady rise in the prevalence of diabetes, it
would not be too daring to predict that the prevalence of DCM will also escalate proportionally in
the upcoming years. Our comprehension of the pathogenic mechanisms of DCM remains limited, in
part due to the difficulty to diagnose the disease at the early stages of its development and also as a
consequence of the scarcity of studies carried out in diabetic patients. Most of our knowledge about
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the pathogenic factors involved in DCM has been provided by studies performed in a variety of rodent
models of type 1 and type 2 diabetes or genetically engineered mouse models that lack important
molecular components of the insulin signaling pathway. These studies have identified mitochondrial
dysfunction, increased AGEs production, oxidative stress, calcium mishandling, lipotoxicity, enhanced
flux through the hexosamine biosynthetic pathway and activation of the RAS pathway as factors
that trigger or contribute to the structural and functional alterations of cardiac cells. Because these
pathogenic factors may concur in the same patient, the use of specific drugs to target one of these
components of the disease might not be sufficient to revert or prevent heart failure. However,
compelling evidence obtained from the studies in rodent models supports the notion that the factors
that mediate the cellular derangements in diabetic hearts are the direct result of impaired insulin
signaling in cardiomyocytes. Therefore, improving insulin signaling in the heart appears as a more
effective strategy for the integral treatment of DCM.
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